| Literature DB >> 25768735 |
Jana Semrau1, Christian Hentschke1, Jana Buchmann2, Karin Meng2, Heiner Vogel2, Hermann Faller2, Hartmut Bork3, Klaus Pfeifer1.
Abstract
BACKGROUND: Improvement of the long-term effectiveness of multidisciplinary ortho-paedic rehabilitation (MOR) in the management of chronic non-specific low back pain (CLBP) remains a central issue for health care in Germany. We developed an interprofessional and interdisciplinary, biopsychosocial rehabilitation concept named "PASTOR" to promote self-management in adults with CLBP and compared its effectiveness with the current model of MOR.Entities:
Mesh:
Year: 2015 PMID: 25768735 PMCID: PMC4359119 DOI: 10.1371/journal.pone.0118609
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Description of PASTOR.
|
|
|
|
|
|
| Introduction to the program, introduction of the rehabilitation team, information about the specific goals and expectations for the rehabilitation stay, education about prevalence, course, and risk factors for the development of acute low back pain (ELBP1, 60minutes) |
| Education about characteristics of low back pain, including; the lack of pathomorphological causes, possibilities and limitations of diagnostic procedures, risk factors for chronic pain development, consequences of pain, and pain memory (ELBP 2, 45minutes) |
| Passive and active therapy options to deal with low back pain; the spine as a fascinating and strong system (ELBP 3, 45minutes) |
| Reflection on patient experiences during the rehabilitation program, counselling regarding recurring pain episodes ("flare ups“), and Red Flags (ELBP 4, 30minutes) final discussion and information about aftercare (ELBP 5, 30minutes) |
|
|
|
|
|
|
| Repetition of key messages of ELBP sessions (BET 1, session 1 to 12) |
| Active play to get to know each other as well as encouraging positive exercise experiences (BET 1, session 1 to 12) |
| Education about positive health effects of physical activity on the body, mood and well-being, Recommendations for health-enhancing physical activities (BET1, session 4 to 5; session 9) |
| Education about the effects of physical activity on the relationship between pain and mood, “physical activity as active pain coping strategy” (BET1, session 6 to 8) |
| Introduction of walking and functional callisthenics and developing control strategies for self-directed execution (e.g. objective vs. subjective methods to measure physical activity intensity level, training documentation, exercise planning) (BET1, session 1 to 4) |
| Practicing lumbar stabilization strategies, activation of deep and global trunk muscles during everyday life and work related physical activities (BET1, session 6 to 8) |
| Action planning and coping planning during the rehabilitation stay (BET1, session 5 to 6) and for home (BET1, session 10 to 11) based on the previous experiences during the rehabilitation stay (see reflection in BET1, session 9) |
| Reflection on the practice of individually planned health-enhancing physical activities and sport activities during the rehabilitation stay (BET1, session 9, see BET2) |
| Discussion of aftercare services (BET1, session 12) |
| More information about a similar BET program, which differs only in duration, is available elsewhere [ |
|
|
|
|
|
|
| Consolidation of movement and regulation competencies for self-directed health-enhancing physical activities/ exercises (e.g. Walking, Nordic-Walking, strength training, aqua-jogging) under therapist supervision (BET2 session 1 to 5) |
| Individual selection of one to two health-enhancing physical activities/ exercises and self-directed performance of the chosen physical activities or exercises during the rehabilitation period (BET2, session 6 to 11) |
|
|
|
|
|
|
| Pain perception and pain management, control of attention (CWP1) |
| Mutual influence of thoughts, feelings/emotions, and body reactions on pain (pain circle); maladaptive and adaptive thoughts when dealing with pain (CWP2) |
| Health-enhancing effects of relaxation and physical activity on pain cycle, the perception of pleasure and enjoyment (CWP3) |
| Fear avoidance behaviour and endurance behaviour, dealing with light and intense pain (CWP4) |
| Stress, work satisfaction and low back pain (CWP5) |
| Dealing with „flare ups“or recurring pain episodes, planning individual coping strategies for everyday life (CWP6) |
|
|
|
|
|
|
| Education about the mode of action and effects of progressive muscle relaxation as well as self-directed practicing and documentation (R1-R4) |
| Self-directed practicing of relaxation (R4-R11) |
|
|
|
|
|
|
| Rehabilitation and retirement, social medical concepts, assessment of performance (WRI 1) |
| The Disabilities Act (SGB IX), Participation benefits and possibilities of vocational rehabilitation (WRI 2) |
Primary and secondary outcome measures.
| Domain/Outcome measure | Questionnaire/Items | Assessment time point | Reference | ||
|---|---|---|---|---|---|
|
| t1 | t2 | t3 | ||
|
| Hannover Functional Ability Questionnaire (FFbH-R) | x | x | x | [ |
|
| |||||
|
| Numeric Rating Scale (NRS) | x | x | x | [ |
|
| Freiburg Questionnaire of physical activity (FFkA) | x | x | [ | |
|
| Short-Form-12 (SF-12) | x | x | x | [ |
|
| Pain Management Questionnaire (FESV) | x | x | x | [ |
| Fear-avoidance and endurance-related responses to pain | Avoidance-Endurance Questionnaire (AEQ) | x | x | x | [ |
|
| sex, age, self-reported work status, severely handicapped | x | [ | ||
t1 = baseline, t2 = end of rehabilitation, t3 = 12-month follow-up
Fig 1Flowchart.
Baseline characteristics of participants consecutively assigned to treatment groups.
| Number Control group/ Intervention group | Control group | Intervention group | |
|---|---|---|---|
|
| |||
| Age (years) M (SD) | 270/266 | 49.3 (8.2) | 48.9 (8.0) |
| Sex, female % | 270/266 | 48.5 | 54.1 |
| Currently in paid employment % | 268/258 | 90.7 | 92.2 |
| On sick leave at the beginning of rehabilitation % | 267/263 | 16.9 | 13.7 |
| Time off work for back pain last six month M (SD) | 269/260 | 20.4 (37.3) | 19.5 (39.7) |
| Severely handicapped pass % | 270/265 | 5 | 3 |
|
| |||
| Functional ability (FFbH-R) M (SD) | 267/265 | 67.1 (19.0) | 71.6 (17.3) |
|
| |||
| Physical component (SF 12) M (SD) | 242/250 | 36.1 (8.4) | 39.2 (8.7) |
| Mental component (SF 12) M (SD) | 242/250 | 47.2 (10.8) | 47.2 (11.6) |
|
| |||
| Back pain intensity (NRS) M (SD) | 267/266 | 5.9 (1.6) | 5.7 (1.7) |
|
| |||
| Total physical activity (hours per week) (FFkA) M (SD) | 270/266 | 8.2 (6.0) | 8.0 (5.5) |
Data in the third and fourth column are either mean values (M) with standard deviation (SD) or percentages as specified in the first column; FFbH-R = Hannover Functional Ability Questionnaire, FFkA = Freiburg Questionnaire of physical activity, SF 12 = Short Form 12, NRS = Numeric Rating Scale
ANCOVA (primary analysis)—primary outcome functional ability (FFbH-R).
| Outcome | Number Control group/ Intervention group | Control group M (SD) | Intervention group M (SD) | adjusted mean difference (95% CI) at the end and at 12 months | between-group effects (ANCOVA) | |
|---|---|---|---|---|---|---|
|
| d | |||||
|
| 182/186 | 66.30 (19.64) | 72.32 (16.81) | |||
|
| 182/186 | 70.94 (18.90) | 79.26 (15.04) | 4.53 (1.91 to 7.16) |
|
|
|
| 182/186 | 68.86 (22.00) | 79.26 (16.17) | 6.58 (3.38 to 9.78) |
|
|
M = mean, SD = standard deviation; CI = confidence interval; ANCOVA = analysis of covariance; P = significance value; bold = significant between-group difference (P<0.05); d = Effect size Cohen’s d for the between group difference; FFbH-R = Hannover Functional Ability Questionnaire
LMM (secondary analysis)—primary outcome functional ability (FFbH-R).
| Outcome | Number Control group/ Intervention group | Control group mean change | Intervention group mean change | adjusted mean difference (95% CI) |
| d |
|---|---|---|---|---|---|---|
|
| 5.07 | 5.97 | 0.91 (-1.43 to 3.24) | 0.447 | 0.03 | |
|
| -2.43 | 0.34 | 2.67 (0.01 to 5.32) |
|
| |
|
| 269/266 | 2.69 | 6.25 | 3.56 (0.45 to 6.67) |
|
|
LMM = linear mixed model; t1 = baseline, t2 = end of rehabilitation, t3 = 12-month follow-up; CI = confidence interval, P = significance value; bold = significant between-group difference (P<0.05); d = Effect size Cohen’s d for the between group difference; FFbH-R = Hannover Functional Ability Questionnaire
Fig 2Boxplots and mean changes for FFbH-R in the CG and IG.
CG = control group, IG = intervention group; FFbH-R = Hannover Functional Ability Questionnaire
ANCOVA (primary analysis)—secondary outcomes SF 12, NRS, FFkA.
| Outcome | Number Control group/ Intervention group | Control group M (SD) | Intervention group M (SD) | adjusted mean difference (95% CI) at the end and at 12 months | between-group effects (ANCOVA) | |
|---|---|---|---|---|---|---|
|
| d | |||||
|
| ||||||
| Baseline (t1) | 156/162 | 36.84 (8.09) | 39.30 (8.71) | |||
| End of rehabilitation (t2) | 156/162 | 41.80 (9.07) | 46.25 (7.38) | 2.99 (1.44 to 4.54) |
|
|
| 12-month follow-up (t3) | 156/162 | 40.27 (9.46) | 44.22 (8.70) | 2.61 (0.79 to 4.42) |
|
|
|
| ||||||
| Baseline (t1) | 156/162 | 47.78 (10.99) | 48.70 (11.02) | |||
| End of rehabilitation (t2) | 156/162 | 54.61 (8.42) | 55.17 (7.34) | 0.06 (-1.50 to 1.63) | 0.937 | 0.06 |
| 12-month follow-up (t3) | 156/162 | 47.85 (11.58) | 50.17 (10.37) | 1.70 (-0.28 to 3.68) | 0.093 | 0.19 |
|
| ||||||
| Baseline (t1) | 179/184 | 5.78 (1.49) | 5.63 (1.66) | |||
| End of rehabilitation (t2) | 179/184 | 4.30 (1.91) | 3.94 (1.81) | -0.21 (-0.53 to 0.12) | 0.213 | 0.13 |
| 12-month follow-up (t3) | 179/184 | 4.79 (2.16) | 4.22 (1.97) | -0.44 (-0.83 to-0.05) |
|
|
|
| ||||||
| Baseline (t1) | 182/186 | 1.19 (1.64) | 1.44 (1.98) | |||
| 12-month follow-up (t3) | 182/186 | 1.62 (2.04) | 2.19 (2.19) | 0.50 (0.10 to 0.90) |
|
|
|
| ||||||
| Baseline (t1) | 182/186 | 8.52 (6.13) | 8.12 (5.05) | |||
| 12-month follow-up (t3) | 182/186 | 11.05 (6.30) | 11.67 (6.01) | 0.87 (-0.30 to 2.04) | 0.146 | 0.16 |
M = mean, SD = standard deviation; CI = confidence interval; ANCOVA = analysis of covariance; P = significance value; bold = significant between-group difference (P<0.05); d = Effect size Cohen’s d for the between group difference; SF 12 = Short Form 12, NRS = Numeric Rating Scale, FFkA = Freiburg Questionnaire of physical activity
ANCOVA (primary analysis)—secondary outcome AEQ.
| Outcome | Number Control group/ Intervention group | Control group M (SD) | Intervention group M (SD) | adjusted mean difference (95% CI) at the end and at 12 months | between-group effects (ANCOVA) | |
|---|---|---|---|---|---|---|
|
| d | |||||
|
| ||||||
|
| ||||||
| Baseline (t1) | 174/176 | 2.18 (1.17) | 2.09 (1.15) | |||
| End of rehabilitation (t2) | 174/176 | 1.54 (1.10) | 1.14 (0.95) | -0.34 (-0.53 to-0.15) |
|
|
| 12-month follow-up (t3) | 174/176 | 2.02 (1.33) | 1.65 (1.14) | -0.29 (-0.52 to-0. 07) |
|
|
|
| ||||||
| Baseline (t1) | 180/180 | 2.20 (1.25) | 2.05 (1.06) | |||
| End of rehabilitation (t2) | 180/180 | 1.91 (1.21) | 1.47 (0.99) | -0.34 (-0.51 to-0.17) |
|
|
| 12-month follow-up (t3) | 180/180 | 2.04 (1.32) | 1.58 (1.05) | -0.34 (-0.55 to-0.13) |
|
|
|
| ||||||
| Baseline (t1) | 181/182 | 0.91 (1.18) | 0.76 (1.09) | |||
| End of rehabilitation (t2) | 181/182 | 0.81 (1.10) | 0.55 (0.90) | -0.15 (-0.31 to 0.01) | 0.062 | 0.20 |
| 12-month follow-up (t3) | 181/182 | 0.91 (1.31) | 0.60 (0.92) | -0.21 (-0.40 to-0.01) |
|
|
|
| ||||||
| Baseline (t1) | 163/158 | 4.05 (1.13) | 3.95 (1.12) | |||
| End of rehabilitation (t2) | 163/158 | 3.83 (1.17) | 3.35 (1.16) | -0.40 (-0.61 to-0.18) |
|
|
| 12-month follow-up (t3) | 163/158 | 3.83 (1.20) | 3.36 (1.11) | -0.36 (-0.57 to-0.15) |
|
|
|
| ||||||
| Baseline (t1) | 160/158 | 2.80 (1.33) | 2.56 (1.42) | |||
| End of rehabilitation (t2) | 160/158 | 2.68 (1.44) | 2.06 (1.25) | -0.46 (-0.68 to-0.23) |
|
|
| 12-month follow-up (t3) | 160/158 | 2.55 (1.45) | 1.90 (1.29) | -0.48 (-0.73 to-0.22) |
|
|
|
| ||||||
|
| ||||||
| Baseline (t1) | 180/178 | 3.42 (1.20) | 3.57 (1.22) | |||
| End of rehabilitation (t2) | 180/178 | 4.03 (1.09) | 4.39 (1.11) | 0.27 (0.07 to 0.47) |
|
|
| 12-month follow-up (t3) | 180/178 | 3.60 (1.25) | 3.91 (1.23) | 0.21 (-0.03 to 0.44) | 0.088 | 0.18 |
|
| ||||||
| Baseline (t1) | 181/182 | 3.45 (1.52) | 3.43 (1.44) | |||
| End of rehabilitation (t2) | 181/182 | 3.43 (1.43) | 3.24 (1.46) | -0.18 (-0.43 to 0.07) | 0.163 | 0.14 |
| 12-month follow-up (t3) | 181/182 | 3.31 (1.50) | 3.22 (1.43) | -0.03 (-0.29 to 0.24) | 0.854 | 0.06 |
|
| ||||||
| Baseline (t1) | 170/164 | 2.64 (1.07) | 2.71 (1.09) | |||
| End of rehabilitation (t2) | 170/164 | 2.83 (1.11) | 3.32 (1.10) | 0.44 (0.23 to 0.64) |
|
|
| 12-month follow-up (t3) | 170/164 | 2.83 (1.11) | 3.27 (1.13) | 0.39 (0.18 to 0.60) |
|
|
|
| ||||||
| Baseline (t1) | 160/157 | 3.34 (0.97) | 3.37 (0.96) | |||
| End of rehabilitation (t2) | 160/157 | 3.37 (0.94) | 3.45 (0.88) | 0.03 (-0.13 to 0.19) | 0.715 | 0.06 |
| 12-month follow-up (t3) | 160/157 | 3.34 (1.08) | 3.44 (0.94) | 0.07 (-0.13 to 0.26) | 0.490 | 0.09 |
M = mean, SD = standard deviation; CI = confidence interval; ANCOVA = analysis of covariance; P = significance value; bold = significant between-group difference (P<0.05); d = Effect size Cohen’s d for the between group difference; AEQ = Avoidance Endurance Questionnaire
ANCOVA (primary analysis)—secondary outcome FESV.
| Outcome | Number Control group/ Intervention group | Control group M (SD) | Intervention group M (SD) | adjusted mean difference (95% CI) at the end and at 12 months | between-group effects (ANCOVA) | |
|---|---|---|---|---|---|---|
|
| d | |||||
|
| ||||||
| Baseline (t1) | 181/183 | 14.91 (4.95) | 14.65 (4.68) | |||
| End of rehabilitation (t2) | 181/183 | 16.61 (4.65) | 18.80 (3.90) | 2.35 (1.54 to 3.16) |
|
|
| 12-month follow-up (t3) | 181/183 | 15.90 (4.85) | 17.88 (4.01) | 2.21 (1.37 to 3.04) |
|
|
|
| ||||||
| Baseline (t1) | 180/183 | 16.16 (4.37) | 16.81 (4.28) | |||
| End of rehabilitation (t2) | 180/183 | 17.04 (3.95) | 19.15 (3.00) | 1.84 (1.20 to 2.49) |
|
|
| 12-month follow-up (t3) | 180/183 | 16.76 (4.37) | 18.44 (3.72) | 1.44 (0.66 to 2.21) |
|
|
|
| ||||||
| Baseline (t1) | 180/183 | 14.22 (4.81) | 14.57 (4.39) | |||
| End of rehabilitation (t2) | 180/183 | 15.46 (4.30) | 18.26 (3.51) | 2.72 (1.98 to 3.47) |
|
|
| 12-month follow-up (t3) | 180/183 | 15.22 (4.46) | 16.95 (3.98) | 1.67 (0.87 to 2.48) |
|
|
|
| ||||||
| Baseline (t1) | 181/185 | 12.27 (4.37) | 12.44 (4.47) | |||
| End of rehabilitation (t2) | 181/185 | 13.05 (4.23) | 15.67 (3.84) | 2.55 (1.83 to 3.27) |
|
|
| 12-month follow-up (t3) | 181/185 | 12.16 (4.38) | 14.89 (4.07) | 2.73 (1.94 to 3.53) |
|
|
|
| ||||||
| Baseline (t1) | 181/184 | 10.55 (4.25) | 11.29 (4.67) | |||
| End of rehabilitation (t2) | 181/184 | 11.71 (4.41) | 14.55 (4.70) | 2.55 (1.69 to 3.40) |
|
|
| 12-month follow-up (t3) | 181/184 | 10.96 (4.56) | 13.81 (4.72) | 2.66 (1.78 to 3.54) |
|
|
|
| ||||||
| Baseline (t1) | 181/184 | 11.92 (5.18) | 11.97 (4.86) | |||
| End of rehabilitation (t2) | 181/184 | 14.31 (4.98) | 16.22 (4.50) | 1.91 (1.06 to 2.77) |
|
|
| 12-month follow-up (t3) | 181/184 | 13.87 (5.00) | 15.01 (4.77) | 1.20 (0.34 to 2.06) |
|
|
M = mean, SD = standard deviation; CI = confidence interval; ANCOVA = analysis of covariance; P = significance value; bold = significant between-group difference (P<0.05); d = Effect size Cohen’s d for the between group difference; FESV = Pain Management Questionnaire